Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease

Study Location:

India

Topic:

Tuberculosis

Enrollment:

Open

Trial Period:

Ongoing

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort (Cohort B). Immunological profiling of TB antigen induced biosignatures, profiling of transcriptional and proteomic biosignatures should provide novel insights into the nature of the immune response that differentiates progressors to TB disease from non-progressors. We aim to measure the plasma biomarker profiles and profile microRNAs at baseline in HHC who progress versus those who do not. We will also measure the unstimulated, TB-antigen and mitogen stimulated cytokine and chemokine responses and unstimulated, TB-antigen and mitogen stimulated growth factors and other immune factors at baseline in HHC who progress versus those who do not to elucidate the differential immune profile between the 2 groups. Our study should provide us new insights into the nature of the immune signatures that differentiate progressors from non-progressor in this cohort.

Aims:
The major objectives of the study are to identify biomarkers that can accurately predict progression from latent TB infection to active TB disease,
To measure the plasma biomarker profiles at baseline in HHC who progress versus those who do not.
To profile microRNAs at baseline in HHC who progress versus those who do not.
To measure the unstimulated, TB-antigen and mitogen stimulated cytokine and chemokine responses at baseline in HHC who progress versus those who do not.
To measure the unstimulated, TB-antigen and mitogen stimulated growth factors and other immune factors at baseline in HHC who progress versus those who do not.

Adult, Pediatric, Household contacts

Categories

Location
Topic

Clinical Trials

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More